Letters to the Editor

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial

Weill Cornell Medical College, New York, NY; New York Presbyterian Hospital, New York
Ulm University Hospital, Ulm
Kent and Canterbury Hospital, Canterbury
Hôpital Saint-Louis, Assistance Publique – Hôpitaux de Paris (AP-HP) and Institut de Recherche Saint-Louis, Université de Paris, Paris
The University of Texas MD Anderson Cancer Center, Houston
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
AZ Sint-Jan Brugge-Oostende AV, Bruges
University Hospital Brno, Brno, Czech Republic
SLK-Kliniken GmbH, MOLIT Institute for Personalized Medicine, Heilbronn
Wilmot Cancer Institute, University of Rochester, New York
Hospital Universitario Central de Asturias, Oviedo
Chang Gung Medical Foundation, Kaohsiung
Evidera, Waltham
Evidera, Waltham
Evidera, Waltham
Celgene, a Bristol-Myers Squibb Company, Boudry
Bristol Myers Squibb, Princeton, NJ; University of Kansas Medical Center, Kansas City
Bristol Myers Squibb, Princeton
Bristol Myers Squibb, Princeton
Celgene, a Bristol-Myers Squibb Company, Boudry
Bristol Myers Squibb, Princeton
The Alfred Hospital and Monash University, Melbourne
Haematologica Early view Sep 23, 2021 https://doi.org/10.3324/haematol.2021.279174